Healthcare Services

Macular Degeneration Treatment Market Insights Highlighting Opportunities and Drivers Supporting Growth to 2030

April 2, 2026April 15, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Macular Degeneration Treatment Market Between 2026 And 2030?

The macular degeneration treatment market has experienced rapid expansion in its size over recent years. It is projected to grow from $12.38 billion in 2025 to $13.81 billion in 2026, at a compound annual growth rate (CAGR) of 11.5%. Historically, this market’s expansion can be attributed to factors such as the aging global population, an increased prevalence of age-related macular degeneration, the clinical success of anti-VEGF injections, improvements in ophthalmic diagnostic capabilities, and growing access to specialized eye care services.

The macular degeneration treatment market is poised for substantial expansion over the next few years. It is projected to achieve a valuation of $20.74 billion by 2030, advancing at a compound annual growth rate (CAGR) of 10.7%. This anticipated growth during the forecast period can be attributed to several factors, including the increasing global elderly population, heightened investment in cutting-edge retinal therapies, a growing emphasis on early-stage amd management, the wider adoption of gene and regenerative therapies, and increased healthcare spending on vision care. Significant trends expected during this period involve a rising focus on early diagnosis and managing disease progression, the expanding use of anti-VEGF therapies, an increasing demand for treatments aimed at long-term vision preservation, the broader availability of minimally invasive treatment options, and greater public awareness of age-related eye disorders.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Macular Degeneration Treatment Market?

The escalating incidence of retinal disorders is projected to boost the expansion of the macular degeneration treatment market. These conditions damage essential eye tissue, interfering with how people process visual information and leading to impaired or absent vision. For example, the American Academy of Ophthalmology estimates that by 2050, roughly 7.32 million individuals in the United States will be affected by primary open-angle glaucoma, a broad classification for various eye ailments, with the highest prevalence observed among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). Within this group, Hispanic men represent the largest demographic. Therefore, the increasing burden of retinal disorders is a significant factor propelling the growth of the macular degeneration treatment market.

Which Market Segments Are Examined In The Macular Degeneration Treatment Market Study?

The macular degeneration treatment market covered in this report is segmented –

1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD

2) By Route of Administration: Oral, Injectable, Other Routes of Administration

3) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals

Subsegments:

1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments

2) By Intermediate AMD: Regular Disease Monitoring and Imaging Surveillance, Risk-Factor Management and Lifestyle Modification

3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options

What Trends Are Affecting The Expansion Of The Macular Degeneration Treatment Market?

Leading companies within the macular degeneration treatment market are concentrating on the creation of biosimilars for age-related macular degeneration (AMD) to enhance the availability of effective therapeutic options. Biosimilars are defined as biological medical products that share a high degree of similarity with an already approved reference product, exhibiting no clinically significant differences in terms of their safety, purity, or potency. For instance, in May 2024, Biocon Biologics Ltd, an Indian-based entity, and Samsung Bioepis Co. Ltd, a company situated in South Korea, secured FDA Approvals for Yesafili and Opuviz, two novel biosimilars. Both these biosimilars operate by inhibiting vascular endothelial growth factor (VEGF), which is known to cause abnormal blood vessel growth in the eye. This mechanism helps in preventing vision loss often associated with conditions like AMD and diabetic retinopathy. The FDA’s approval procedure involved comparative investigations that demonstrated no noteworthy distinctions in the efficacy or safety of Yesafili and Opuviz when compared to Eylea. These studies meticulously assessed the pharmacokinetics and immunogenicity of the biosimilars.

Who Are The Primary Competitors In The Macular Degeneration Treatment Market?

Major companies operating in the macular degeneration treatment market are F Hoffmann La Roche Ltd, Regeneron Pharmaceuticals Inc, Novartis AG, Bayer AG, Allergan Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio Inc, Aerie Pharmaceuticals Inc, Kodiak Sciences Inc, Neurotech Pharmaceuticals Inc, Regenxbio Inc, Adverum Biotechnologies Inc, Applied Genetic Technologies Corp, 4D Molecular Therapeutics Inc, GenSight Biologics SA, Nanoscope Therapeutics Inc, Annexon Inc, Ocular Therapeutix Inc, Graybug Vision Inc

Read the full macular degeneration treatment market report here:

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

What Are The Leading Geographic Regions In The Macular Degeneration Treatment Market?

North America was the largest region in the macular degeneration treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Macular Degeneration Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=5799&type=smp

Browse Through More Reports Similar to the Global Macular Degeneration Treatment Market 2026, By The Business Research Company

Antibiotics Global Market Report

https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

Peptide Antibiotics Global Market Report

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Veterinary Antibiotics Global Market Report

https://www.thebusinessresearchcompany.com/report/veterinary-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795